

**CIRM Scientific and Medical Research Funding Working Group
Biographical information of candidates nominated to serve as
Scientific Members of the Working Group**

Willard H. Dere, MD

Dr. Dere is Executive Director Personalized Health and Professor of Medicine at the University of Utah. Prior to joining the University, Dr. Dere served for 11 years at Amgen, Inc. in executive positions; his last as Senior Vice President, Global Development and Corporate Chief Medical Officer. Dr. Dere also served for a number of years in senior positions at Ely Lilly in Endocrine, Bone, and General Medicine Research and Development. Dr. Dere earned his MD at the University of California, Davis; completed his internship and residency at the University of Utah in Internal Medicine; and completed his postdoctoral training at the University of California, San Francisco in Endocrinology and Metabolism.

Dr. Dere has over 25 years of experience in the pharma industry; has lead the clinical development of three bone-active medicines, raloxifene, rPTH 1-34, and denosumab, and several others in the oncology, inflammation, and nephrology therapeutic areas; and has 7 patents. Dr. Dere is experienced in research and development, regulatory affairs, and translational and clinical medicine and is Board certified in Internal Medicine and is a Fellow in the American College of Physicians.

Malin P. Parmar, PhD

Dr. Parmar is Associate Professor at the Department of Experimental Medical Science at Wallenberg Neuroscience Centre and Lund Stem Cell Centre at Lund University. She earned her Bachelor of Science at Simon Fraser University in Canada and her PhD in Medical Sciences and Developmental Biology at Lund University. Dr. Parmar completed two postdoctoral fellowships; one at Edinburgh University (financed by the Swedish Research Council) and another at Lund University.

Dr. Parmar's group works with translational stem cell biology. The focus of her research is to understand cell fate specification in the developing brain and in human neural progenitor cells using cell-based models of neuronal differentiation. The laboratory's current focus is to learn how to direct and efficiently drive controlled differentiation of human stem cells into subtype-specific neurons. Her laboratory has also developed technologies for direct conversion of human fibroblasts into functional and subtype-specific neurons *in vitro*, and the conversion of endogenous glia into neurons *in vivo*. The ultimate aim is to develop these cells and technologies for use in brain repair, with focus on Parkinson's disease.

To that end, Dr. Parmar is involved in TRANSEURO, a European study that is now at the stage of transplanting fetal cells into patients with Parkinson's disease as part of a new clinical trial; NueroStemcellRepair, a European stem cell consortium looking at neural cell replacement, reprogramming and functional brain repair, also with a focus on Parkinson's; and GForce-PD, a global task force for developing stem cell therapy for Parkinson's. This involves research teams in the US, Europe and Japan

working together to standardize research and clinical protocols for Parkinson's disease. Dr. Parmar also served as the Training and Networking Director for 7th framework EU program NeuroStemcell. She is involved in teaching at the medical, biomedical and PhD program and is Co-Director of Research School in Stem Cell Biology at Lund University and currently serves on the Swedish Parkinson Foundation Scientific Committee.